NCT06400251View on ClinicalTrials.gov

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

June 27, 2023

Study Completion Date

December 31, 2025

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Ipatasertib

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH